01. Pre-clinical data (module 1)
This first module will go through the various steps that led to the concept of Metronomic Chemotherapy, demonstrating how this latter method (administering chemotherapy drugs more frequently at a lower dose) causes a far more potent anti-tumor effect than the respective maximum tolerated dose (MTD) protocol.
The evidence of potentially strong antiangiogenic effects of chemotherapy were provided by the late Judah Folkman’s lab. Where he and his team found that even though conventional MTD had an antiangiogenic effect, the beneficial side effect was reversed during the long break periods between successive treatments of MTD chemotherapy. Breaks, necessary to allow recovery from the toxic side effects, due to the chemotherapy, which also allowed to repair the tumors’ vasculature, thus negating the supposedly
desirable tumor vascular targeting effects of the chemotherapy. These revelations led to assume that on the otherhand administering chemotherapy drugs more frequently, at a lower dose caused a stronger anti-tumor effect.
In part two of the module, you will be given a presentation of some of the mechanisms that mediate antitumor efficacy through metronomic chemotherapy, plus additional effects such as anti-vascular, immune stimulating, and direct tumor cell targeting ones.
The third part of the module will walk you through, more in depth, on the additional effects of metronomic chemotherapy that were mentioned in the previous presentation.
The fourth part of the module will give you an illustration on the association of metronomic chemotherapy with drug repurposing, which consists in using drugs that were not originally developed to treat cancer.
- Lectures 16
- Quizzes 1
- Duration 1 hour
- Skill level All levels
- Language English
- Students 8
- Assessments Yes
LESSON 1 ROBERT KERBEL
Genesis of the Concept of Metronomic Chemotherapy
LESSON 2 ROBERT KERBEL
Metronomic Chemotherapy: (Re)assessing its anti-tumor mechanisms using preclinical models of metastatic disease
LESSON 3 EDDY PASQUIER
Metronomic chemotherapy: from anti-angiogenesis to multi-targeted therapy
LESSON 4 EDDY PASQUIER
Metronomic chemotherapy in combination with drug repurposing
The quiz is mandatory only for those willing to achieve European CME credits. Please be aware that the ISMe® educational e-learning platform is in the process of being accredited by the European Accreditation Council for Continuing Medical Education (UEMS-EACCME)